Can methotrexate be administered to a breastfeeding mother during lactation?

Methotrexate Should Be Avoided During Lactation

Breastfeeding should be avoided among mothers on methotrexate, as the active metabolite 7-hydroxymethotrexate is detectable in breast milk and poses potential harmful effects to the infant, despite limited data showing no adverse effects in the few reported cases. 1, 2

Primary Recommendation

The most recent and highest-quality guideline evidence from 2025 clearly states that breastfeeding should be avoided among mothers on methotrexate 1. This recommendation is based on:

• Presence of active metabolite: While methotrexate itself has a low relative infant dose (RID) of 0.11%, the active metabolite 7-hydroxymethotrexate is detectable in breast milk and may accumulate in neonatal tissues 1, 2, 3
• Limited safety data: Only a few cases of breastfeeding during methotrexate treatment have been reported 1
• Potential for harm: Despite no adverse effects noted in the limited case reports, the theoretical risk of toxicity remains significant 1

Exception: When No Alternative Exists

If low-dose methotrexate (≤25 mg/week) is used and no alternative drug compatible with breastfeeding is available, and the mother strongly desires breastfeeding, it may be considered ONLY with close monitoring of the infant 1, 4. This exception requires:

Specific Conditions for Consideration:

• Maximum dose of 25 mg/week
• No safer alternative medication available
• Strong maternal desire to breastfeed
• Ability to implement close infant monitoring

Risk Mitigation Strategy:

• Avoid breastfeeding within the first 24 hours after methotrexate intake (when infant exposure decreases by 40%) 1
• Clinical and biochemical monitoring of the infant should be implemented 1
• This remains a conditional recommendation with very low-quality evidence 2

Supporting Evidence Across Guidelines

Multiple guidelines consistently recommend against methotrexate during lactation:

• 2025 Global IBD Consensus: Breastfeeding should be avoided 1
• 2025 EULAR Recommendations: Methotrexate may be considered only if no alternative exists and with very low amounts in milk 4
• 2016 Toronto Consensus: Suggests avoiding methotrexate therapy (GRADE: Conditional recommendation, very low-quality evidence, 100% agreement) 2
• 2020 ACR Guidelines: Conditionally recommend against use while breastfeeding due to potential accumulation in neonatal tissues 5

Key Pharmacokinetic Data

• Milk-to-plasma ratio: 0.08:1 2
• Relative infant dose: 0.11% 1, 3
• Methotrexate exposure decreases by 40% at 24 hours post-dose 1
• Both methotrexate and 7-hydroxymethotrexate reach minimum concentrations over 24 hours 3

Critical Pitfalls to Avoid

1. Do not rely solely on the low RID: The presence of the active metabolite is the primary concern, not just the parent drug
2. Do not assume safety based on limited case reports: The few reported cases without adverse effects do not establish safety given the theoretical risks
3. Do not confuse with pregnancy contraindication: Methotrexate is absolutely contraindicated in pregnancy 6, but lactation carries a different risk profile with potential for conditional use in exceptional circumstances

Practical Clinical Approach

First-line approach: Switch to a lactation-compatible medication (e.g., azathioprine, TNF inhibitors, hydroxychloroquine) before initiating breastfeeding 1, 5

If methotrexate cannot be discontinued:

1. Counsel mother on risks to infant
2. Discuss alternative feeding options
3. Only proceed with breastfeeding if all exception criteria are met
4. Implement 24-hour pump-and-discard strategy after each dose
5. Establish infant monitoring protocol (clinical assessment, complete blood count, liver function tests)

The safest recommendation remains to avoid breastfeeding entirely while on methotrexate therapy.